243 related articles for article (PubMed ID: 22573234)
1. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis.
Lin CJ; Nasr Z; Premsrirut PK; Porco JA; Hippo Y; Lowe SW; Pelletier J
Cell Rep; 2012 Apr; 1(4):325-33. PubMed ID: 22573234
[TBL] [Abstract][Full Text] [Related]
2. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.
Lin CJ; Cencic R; Mills JR; Robert F; Pelletier J
Cancer Res; 2008 Jul; 68(13):5326-34. PubMed ID: 18593934
[TBL] [Abstract][Full Text] [Related]
3. Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.
Robert F; Roman W; Bramoullé A; Fellmann C; Roulston A; Shustik C; Porco JA; Shore GC; Sebag M; Pelletier J
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13421-6. PubMed ID: 25197055
[TBL] [Abstract][Full Text] [Related]
4. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
5. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy.
Lin CJ; Malina A; Pelletier J
Cancer Res; 2009 Oct; 69(19):7491-4. PubMed ID: 19773439
[TBL] [Abstract][Full Text] [Related]
6. Targeting the eIF4F translation initiation complex for cancer therapy.
Konicek BW; Dumstorf CA; Graff JR
Cell Cycle; 2008 Aug; 7(16):2466-71. PubMed ID: 18719377
[TBL] [Abstract][Full Text] [Related]
7. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
[TBL] [Abstract][Full Text] [Related]
8. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun SY
Neoplasia; 2010 Oct; 12(10):848-55. PubMed ID: 20927323
[TBL] [Abstract][Full Text] [Related]
9. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma.
Kelly PN; Puthalakath H; Adams JM; Strasser A
Blood; 2007 Jun; 109(11):4907-13. PubMed ID: 17317859
[TBL] [Abstract][Full Text] [Related]
10. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
[TBL] [Abstract][Full Text] [Related]
11. SUMO-2 promotes mRNA translation by enhancing interaction between eIF4E and eIF4G.
Chen LZ; Li XY; Huang H; Xing W; Guo W; He J; Sun ZY; Luo AX; Liang HP; Hu J; Wang ZG; Xu YS; Xu X
PLoS One; 2014; 9(6):e100457. PubMed ID: 24971752
[TBL] [Abstract][Full Text] [Related]
12. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
13. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.
Pelletier J; Graff J; Ruggero D; Sonenberg N
Cancer Res; 2015 Jan; 75(2):250-63. PubMed ID: 25593033
[TBL] [Abstract][Full Text] [Related]
14. Altering chemosensitivity by modulating translation elongation.
Robert F; Carrier M; Rawe S; Chen S; Lowe S; Pelletier J
PLoS One; 2009; 4(5):e5428. PubMed ID: 19412536
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.
Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A
Genome Biol; 2014; 15(10):476. PubMed ID: 25273840
[TBL] [Abstract][Full Text] [Related]
16. Developing anti-neoplastic biotherapeutics against eIF4F.
Steinberger J; Chu J; Maïga RI; Sleiman K; Pelletier J
Cell Mol Life Sci; 2017 May; 74(9):1681-1692. PubMed ID: 28004147
[TBL] [Abstract][Full Text] [Related]
17. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic co-operation in beta-cell tumorigenesis.
Pelengaris S; Khan M
Endocr Relat Cancer; 2001 Dec; 8(4):307-14. PubMed ID: 11733227
[TBL] [Abstract][Full Text] [Related]
19. Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation.
Fagan DH; Fettig LM; Avdulov S; Beckwith H; Peterson MS; Ho YY; Wang F; Polunovsky VA; Yee D
Horm Cancer; 2017 Aug; 8(4):219-229. PubMed ID: 28577281
[TBL] [Abstract][Full Text] [Related]
20. Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
Issaenko OA; Bitterman PB; Polunovsky VA; Dahlberg PS
Cancer Gene Ther; 2012 Sep; 19(9):609-18. PubMed ID: 22767218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]